DailyIQ
|
Sector:HealthcareAll sectors
Last updated 6 minutes ago

TMO·Thermo Fisher Scientific Inc.

$.
+. (+.%)
After Hours
High
$533.08
Open
$525.50
Market Cap
195.48B
52W High
$643.99
Low
$522.60
P. Close
$527.04
P/E
28.55
52W Low
$403.36
Fwd P/E
19.34
DailyIQ Est.
$616.99
Technical Score (1D)
95
BUY
News Sentiment
53
MIXED
TMO just announced a quarterly cash dividend of $0.47 per share, payable on Oct 15 2026, marking a continuation of its long‑term dividend growth policy. The dividend declaration signals management’s confidence in cash‑flow stability and may attract income‑focused investors in the coming week. Because the payout is scheduled for mid‑October, traders should anticipate a potential short‑term rally as the ex‑dividend date approaches, but the impact is likely modest given the company’s already high dividend yield. The dividend also reinforces TMO’s commitment to returning value, which could mitigate some of the downside pressure from recent concerns over NIH funding and Chinese market exposure. In the broader context, the Q2 earnings preview, released 17.8 hours ago, highlighted a 12 % YTD decline driven by those same headwinds, underscoring the importance of upcoming guidance on product pipeline performance. If TMO’s Q2 guidance shows stronger revenue growth or cost containment, it could offset the dividend’s neutral effect and support a more bullish stance over the next 10 trading days. Conversely, any surprise downgrade in the pipeline or regulatory setbacks could dampen the dividend’s positive sentiment and lead to a re‑evaluation of the stock’s valuation. Traders should watch the earnings release for updates on NIH funding levels, Chinese market sales, and any new regulatory approvals that could materially alter the company’s outlook. Additionally, monitoring the ex‑dividend date and any subsequent capital allocation guidance will be key to assessing whether the dividend is a one‑off signal or part of a broader shift toward higher returns.
Earnings Summary
Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, is a global leader in scientific research and laboratory solutions, offering a broad portfolio of reagents, instruments, and specialty diagnostics that serve the life sciences, analytical, and biopharma sectors. In the last two quarters, the company reported Q4 2025 revenue of $12.215 billion and EPS of $6.57, a decline from Q1 2026 revenue of $11.005 billion and EPS of $5.44; the prior two quarters (Q2 2025 and Q3 2025) saw revenue growth from $10.855 billion to $11.122 billion and EPS rise from $5.36 to $5.79, indicating a recent slowdown in momentum. Across the six most recent quarters, Thermo Fisher has consistently beat earnings estimates—five of six quarters produced EPS above consensus, with the only miss occurring in Q1 2026 where EPS fell short of the $5.74 estimate. Historically, the company has delivered double‑digit revenue growth year‑over‑year, with Q4 2024 revenue at $11.395 billion rising to $12.215 billion in Q4 2025, while EPS grew from $6.10 to $6.57; however, the Q1 2026 EPS dip signals a potential shift in profitability dynamics. Recent news highlights a modest price‑target cut by Evercore ISI to $570 amid concerns about earnings outlook and competitive pressure, a divestiture of the microbiology unit for $1.075 billion that is expected to dilute EPS, and the launch of upgraded Orbitrap mass spectrometers with AI‑enabled software at BIO 2026, which could enhance service revenue. Investors should watch the upcoming Q2 2026 earnings release for guidance on revenue mix, margin trends, and the adoption rate of the new AI‑driven tools, as these factors will likely shape short‑term valuation and earnings expectations.

EPS

EstBeatMiss
$4.88$5.36$5.84$6.31$6.79Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$5.71 - -
Q1'26$5.74$5.44-5.2%
Q4'25$6.51$6.57+0.9%
Q3'25$5.50$5.79+5.3%
Q2'25$5.23$5.36+2.5%
Q1'25$5.10$5.15+0.9%

Revenue

EstBeatMiss
$10.1B$10.7B$11.3B$11.9B$12.5BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$11.7B - -
Q1'26$11.8B$11.0B-6.7%
Q4'25$12.1B$12.2B+1.2%
Q3'25 - $11.1B -
Q2'25 - $10.9B -
Q1'25 - $10.4B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

TMO Stock Snapshot

TMO is currently trading at $523.85, giving Thermo Fisher Scientific Inc. a market cap of 195.48B and a P/E ratio of 28.6. Today's range spans $522.60–$533.08, with shares opening at $525.50 and moving down $3.19 (0.6%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY) with a news sentiment reading of 53/100.

Over the past year TMO has traded between $403.36 and $643.99 - the current price is +29.9% off the 52-week low and -18.7% from the high. 38 analysts cover the stock with a Buy consensus and a mean 12-month target of $590.77 (range $490.00–$750.00), implying upside of +12.8%.

Growth-oriented Healthcare investors looking for technical confirmation find it in TMO: BUY signal, 95/100 score, neutral sentiment at 53/100, price $523.85 (in the middle of its 52-week range). The current P/E ratio stands at 28.6. The 195.48B market cap is the sweet spot - big enough to absorb institutional sizing, small enough to move materially on conviction. Annual range: $403.36–$643.99.

The combination of a BUY signal (95/100) and neutral news sentiment (53/100) puts TMO on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 195.48B in Healthcare market cap without immediately moving the stock. At $523.85 (in the middle of its 52-week range in the $403.36–$643.99 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.